RxDoctor Payments DataLook up a doctor →

Sunita Tummala

Neurology · Flint, MINPI 1568537207

Payments from drug & device makers

$377,617in general payments, 2019–2025

Across 1,418 payments — averaging $266.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$161K
  • Biogen$93K
  • AstraZeneca$84K
  • Pfizer$19K
  • Biohaven Pharmaceutical Holding Company Ltd.$8K
  • EMD Serono, Inc.$3K
  • plus $9K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)420$161,109
Biogen234$93,371
AstraZeneca(2 entities)134$83,938
Pfizer26$18,967
Biohaven Pharmaceutical Holding Company Ltd.15$7,844
EMD Serono, Inc.93$2,837
Novartis68$1,041
UCB, Inc.39$824
Supernus Pharmaceuticals, Inc.34$501
Teva Pharmaceuticals USA, Inc.22$424
Genentech USA, Inc.20$395
Sanofi17$359
Neurelis, Inc.16$353
Neurocrine Biosciences, Inc.13$345
Amgen(2 entities)16$323
Lilly USA, LLC15$288
Alnylam Pharmaceuticals Inc.13$262
Bristol Myers Squibb19$259
Lundbeck LLC12$241
Otsuka America Pharmaceutical, Inc.10$241
SK Life Science, Inc.9$205
Aquestive Therapeutics, Inc.11$190
Jazz Pharmaceuticals Inc.8$186
Argenx US, Inc.4$163
Catalyst Pharmaceuticals, Inc.7$162
Eisai Inc.7$157
Acadia Pharmaceuticals Inc8$152
Upsher-smith Laboratories LLC7$146
Johnson & Johnson(2 entities)6$132
Sunovion Pharmaceuticals Inc.9$130
E.r. Squibb & Sons, L.L.C.7$129
Zyla Life Sciences, Inc.8$125
Vanda Pharmaceuticals Inc.5$124
Kyowa Kirin, Inc.7$123
TG Therapeutics, Inc.5$117
Takeda Pharmaceuticals U.S.A., Inc.4$108
Greenwich Biosciences, Inc.4$107
Corium, LLC6$102
Amneal Pharmaceuticals LLC5$99
Adamas Pharmaceuticals, Inc.5$86
Acorda Therapeutics, Inc4$82
Avanir Pharmaceuticals, Inc.5$75
Ipsen Biopharmaceuticals, Inc3$71
Currax Pharmaceuticals LLC5$67
Tanabe Pharma America, Inc.3$64
Biohaven Pharmaceuticals, Inc.2$64
Aucta Pharmaceuticals, Inc.3$63
Octapharma USA, Inc.3$55
MDD US Operations, LLC3$46
Janssen Scientific Affairs, LLC1$44
Axsome Therapeutics, Inc.2$42
Tersera Therapeutics LLC1$31
GE HealthCare2$28
GRT US Holding, Inc.2$27
Mallinckrodt Enterprises LLC1$26
Livanova USA, Inc.1$22
Sumitomo Pharma America, Inc.2$22
CSL Behring1$21
Avadel CNS Pharmaceuticals, LLC1$19
Sandoz1$19

How this compares

$377,617 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan →

Medicare billing

Part B allowed, 2024
$1,333,885
Medicare patients
536
Services billed
30,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Flint

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →